Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics.
5. In at five, this week is the positive outcome announcement for the trials evaluating Praluent.
Positive results from trials evaluating Praluent announced
4. Brexit and its regulatory implications make it into fourth position with this article from Schlafender Hase.
In imperfect harmony? What will Brexit mean for regulatory harmonisation
3. Taking the middle position is the news that the biosimilar Truxima is non-inferior to the reference product.
Biosimilar, Truxima, is non-inferior to the reference product, notes study
2. Coming in second place is the study from the Reputation Institute finding that pharma companies have strong reputations.
Stake pharma’s reputation on it! Study finds pharma companies are reputable but competition is tight
1. This week’s top spot goes to the launch of the fast track acceleration programme for life sciences start-ups.